German
|
English
|
French
Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Home
<
List for "N07AA" (5)
–
Sort according to Concentration, Size and Price
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Package Size
EFP
CP
SB
DC
Composition
Registr. Holder
Category
Pyridostigmine (N07AA02) 4 products
WHO-DDD
DrugBank.ca
IP
CI
Mestinon
150 Dragée(s)
39.02
58.85
10 %
Dragées: Pyridostigmini Bromidum 60 mg
Rhythm
Pharmaceuticals
Switzerland GmbH
B / SL
FB
G
IP
CI
Mestinon
250 Tablet(s)
13.43
31.00
10 %
Tablets: Pyridostigmini Bromidum 10 mg
Rhythm
Pharmaceuticals
Switzerland GmbH
B / SL
FB
G
IP
CI
Mestinon retard
100 Tablet(s)
k.A.
Tablets: Pyridostigmini Bromidum 180 mg
Rhythm
Pharmaceuticals
Switzerland GmbH
B
FB
G
IP
CI
Mestinon retard
100 Tablet(s)
k.A.
Tablets: Pyridostigmini Bromidum 180 mg
Rhythm
Pharmaceuticals
Switzerland GmbH
B
FB
G
Neostigmine, Combinations (N07AA51) 1 products
WHO-DDD
DrugBank.ca
IP
Robinul-Neostigmina
10 1 ampoule(s)
k.A.
Injection solution: 2 Active Agents
Sintetica SA
B
FB
G
show caption
Red = Original
CM
= Co-Marketing
EFP = Ex-Factory-Price, exkl. VAT CHF
Green = Generic Drug
V/S
= vaccine/blood product
CP = Consumer Price, inkl. VAT CHF
Black = not classified
A
= Anesthetic
PR = Price request
Gray background = Pending Permission Extension
SIP
= Short Information for Professionals
SB = Selbstbehalt
H
= Homeopathics
IP
= Information for Professionals
DC = Daily Cost
A
= Anthroposophics
CI
= Consumer Information
SL = Official reimbursement list of Switzerland.
Ph
= Phytotherapeutics
L
= Limitations
SO = Original according to SL
Cas Reg.Nr. = CAS Registry
G
= Google Search by Product Name
SG = Generic according to SL
P
= Import parallel
FB
= Drugs Feedback
LPPA = Liste des produits pharmaceutiques pour application spéciale
Legal Disclaimer
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2026
©ywesee GmbH
Settings
|
Help
|
Login
|
Contact
|
Home
